Cargando…
Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532950/ https://www.ncbi.nlm.nih.gov/pubmed/33011825 http://dx.doi.org/10.1007/s00228-020-03008-6 |
| _version_ | 1783590032950427648 |
|---|---|
| author | Kow, Chia Siang Aldeyab, Mamoon Hasan, Syed Shahzad |
| author_facet | Kow, Chia Siang Aldeyab, Mamoon Hasan, Syed Shahzad |
| author_sort | Kow, Chia Siang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7532950 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75329502020-10-05 Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 Kow, Chia Siang Aldeyab, Mamoon Hasan, Syed Shahzad Eur J Clin Pharmacol Letter to the Editor Springer Berlin Heidelberg 2020-10-04 2021 /pmc/articles/PMC7532950/ /pubmed/33011825 http://dx.doi.org/10.1007/s00228-020-03008-6 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Kow, Chia Siang Aldeyab, Mamoon Hasan, Syed Shahzad Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 |
| title | Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 |
| title_full | Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 |
| title_fullStr | Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 |
| title_full_unstemmed | Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 |
| title_short | Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 |
| title_sort | quality of adverse event reporting in clinical trials of remdesivir in patients with covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532950/ https://www.ncbi.nlm.nih.gov/pubmed/33011825 http://dx.doi.org/10.1007/s00228-020-03008-6 |
| work_keys_str_mv | AT kowchiasiang qualityofadverseeventreportinginclinicaltrialsofremdesivirinpatientswithcovid19 AT aldeyabmamoon qualityofadverseeventreportinginclinicaltrialsofremdesivirinpatientswithcovid19 AT hasansyedshahzad qualityofadverseeventreportinginclinicaltrialsofremdesivirinpatientswithcovid19 |